CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma

Rumeng Zhang; Zhihao Wang; Huan Wang; Lin Li; Lin Dong; Lin Ding; Qiushuang Li; Linyan Zhu; Tiantian Zhang; Yong Zhu; Keshuo Ding

doi:10.17305/bb.2024.10397

Biomolecules & Biomedicine (Jul 2024)

CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma

Rumeng Zhang,
Zhihao Wang,
Huan Wang,
Lin Li,
Lin Dong,
Lin Ding,
Qiushuang Li,
Linyan Zhu,
Tiantian Zhang,
Yong Zhu,
Keshuo Ding

Affiliations

Rumeng Zhang: Department of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
Zhihao Wang: Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
Huan Wang: Department of Anesthesiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Lin Li: Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
Lin Dong: Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
Lin Ding: Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
Qiushuang Li: Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China
Linyan Zhu: Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China
Tiantian Zhang: Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China
Yong Zhu: Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China
Keshuo Ding: Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China; Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

DOI: https://doi.org/10.17305/bb.2024.10397

Abstract

Read online

Colon cancer, thyroid cancer, and melanoma are common malignant tumors that seriously threaten human health globally. The B-Raf proto-oncogene, serine/threonine kinase (BRAF)(V600E) mutation is an important driver gene mutation in these cancer types. In this study, we identified that collagen triple helix repeat containing 1 (CTHRC1) expression was associated with the BRAF(V600E) mutation in colon cancer, thyroid cancer, and melanoma. Based on database analysis and clinical tissue studies, CTHRC1 was verified to correlate with poor prognosis and worse clinicopathological features in colon cancer and thyroid cancer patients, but not in patients with melanoma. Several signaling pathways, immune cell infiltration, and immunotherapy markers were associated with CTHRC1 expression. Additionally, a high level of CTHRC1 was correlated with decreased sensitivity to antitumor drugs (vemurafenib, PLX-4720, dabrafenib, and SB-590885) targeting the BRAF(V600E) mutation. This study provides evidence of a significant correlation between CTHRC1 and the BRAF(V600E) mutation, suggesting its potential utility as a diagnostic and prognostic biomarker in human colon cancer, thyroid cancer, and melanoma.

Published in Biomolecules & Biomedicine

ISSN: 2831-0896 (Print); 2831-090X (Online)
Publisher: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
Country of publisher: Bosnia and Herzegovina
LCC subjects: Science: Biology (General)
Website: http://biomolbiomed.com/

About the journal

Abstract

Keywords